Individual antibody attributes are difficult to distinguish and quantify when mixed in a single formulation. Resolving this allows for precise stability monitoring and regulatory compliance of multi-drug products.

Biologic molecules suffer from physical and chemical degradation during storage and administration. Preventing structural breakdown ensures therapeutic potency and reduces immunogenic risks.

Insufficient binding affinity and rapid viral escape from existing immune responses. Overcoming this limitation ensures sustained protection against respiratory syncytial virus infection.